Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 2, 2005, Pages 216-219

  Prammananan, T ^a   Arjratanakool, W ^a   Chaiprasert, A ^a   Tingtoy, N ^a   Leechawengwong, M ^a   Asawapokee, N ^a   Leelarasamee, A ^a   Dhiraputra, C ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

MDR TB; Second line drugs; Susceptibility

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ETHIONAMIDE; KANAMYCIN; OFLOXACIN;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; THAILAND;

AMIKACIN; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; KANAMYCIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; P-AMINOSALICYLIC ACID; THAILAND;

EID: 14044272121     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione M C, for the WHO Global Surveillance and Monitoring Project. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1994; 282: 677-686.
2. Murray C J, Salomon J A. Modeling the impact of global tuberculosis strategies. Proc Natl Acad Sci USA 1998; 338: 13881-13886.
3. Pablos-Méndez A, Raviglione M C, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998; 338: 1641-1649.
4. Bastian I, Rigouts L, Van Deun A, Portaels F. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull World Health Organ 2000; 78: 238-251.
5. Kent P T, Kubica G P. Public health mycobacteriology. A guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 1985.
6. Boettger E C. Resistance to drug targeting protein biosynthesis in mycobacteria. Trends Microbiol 1994; 2: 416-421.
7. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. Selection of gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170: 479-483.
8. Sullivan E A, Kreiswirth B N, Palumbo L, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995; 345: 1148-1150.
9. Rastogi N, Labrousse V, Goh K S. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and conparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-175.
10. National Committee for Clinical Laboratory Standards. Antimycobacterial susceptibility testing for Mycobacterium tuberculosis. Tentative standard M24-T. Wayne, PA: NCCLS, 1995.
11. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A. Wayne, PA: NCCLS, 2003.
12. Tenover F C, Crawford J T, Huebner R E, et al. The resurgence of tuberculosis: is your laboratory ready? J Clin Microbiol 1993; 31: 767-770.